Do they give a 3 year old the same dose of vaccine they give an adult?

Question

My granddaughter has had a flu vaccine for the past 2 years but only one shot which was half a dose. She never received the other dose due to time or sickness. Now they tell me she should receive an adult dose this year because she is over three.

Answer 1

Children over 3 usually get .5mls of the vaccine just like an adult. My son is 5 and got his big dose. Children under three get a .25 ml dose but its a child version of the vaccine not just a smaller dose of the big stuff. My niece missed her second shot the first time she got it and they did her the same way they are suggesting for your grand daughter. Seemed to work she did not get the flu

Answer 2

This Site Might Help You.

RE:
Do they give a 3 year old the same dose of vaccine they give an adult?
My granddaughter has had a flu vaccine for the past 2 years but only one shot which was half a dose. She never received the other dose due to time or sickness. Now they tell me she should receive an adult dose this year because she is over three.

Answer 3

Yes, they were supposed to give her half and then soon after, the other half, the FIRST time she got the flu shot. Eventhough she only got half for 2 years.

So, since this isn't her first time, yes she will get the whole thing. Just make sure you give her some Children's Tylenol or Ibuprofen BEFORE you take her for the shot, and then as directed after the shot. She may get a slight fever and be a little achy.

Answer 4

Yes she would get an adult dose at that age.

Answer 5

If the doctor you know and trust said it then maybe

Answer 6

Yes, the Immune Response is Essentially the Same.

I Personally Would Like to See Intrademal Administration of Many Vaccines, Especially if it is In Short Supply:


I came Accross many Things you Might Find Interesting:

Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-year follow-up study.
Kurugöl Z - Vaccine - 16-JUL-2001; 19(28-29): 3936-9
From NIH/NLM MEDLINE

NLM Citation ID:
11427268 (PubMed)
21321108 (MEDLINE)

Full Source Title:
Vaccine

Publication Type:
Journal Article

Language:
English

Author Affiliation:
Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Turkey. [e-mail]

Authors:
Kurugöl Z; Erensoy S; Akſit S; Egemen A; Bilgiç A

Abstract:
Several studies have documented the efficacy of low-dose intradermal administration of hepatitis B vaccine. However, little is known about the duration of protection provided by low-dose intradermal administration of hepatitis B vaccine. This study reports results from a 5-year follow up period of 200 healthy children (100 infants and 100 preschool children) immunized intradermally with 2 microg doses of recombinant hepatitis B vaccine (GenHevac B) at months 0,1, and 6. In the 8th week after the third vaccine dose, 97% of the children developed anti-HBs antibodies higher than or equal to 10 mlU ml(-1), and the antiHBs geometric mean titre (GMT) was 676 mlU ml(-1). In month 18 and year 5, the anti-HBs GMT decreased to approximately one-third (220 mlU ml(-1)) and one-tenth (68 mlU ml(-1)) of the initial levels, respectively. However, 87% of the children had protective levels of anti-HBs (> or =10 mlU ml(-1)) after 5 years. Among 156 children followed for 5 years, none became positive for anti-HBc and/or HbsAg. Seven children who were seronegative after 5 years developed anti-HBs antibodies higher than 1000 mlU ml(-1) after an additional 10 microg intramuscular hepatitis B vaccine. Persistent immunologic memory over periods of 5 years or more is evident, the anamnestic antibody response to a booster dose of vaccine, even in these children who have lost antibody. We conclude that intradermal administration of 2 microg recombinant hepatitis B vaccine provides long-term protection against hepatitis B virus in infants and preschool children.

Major Subjects:

* Hepatitis B Vaccines / * administration & dosage

Additional Subjects:

* Child
* Child, Preschool
* Female
* Follow-Up Studies
* Hepatitis B Antibodies / blood
* Human
* Immunization Schedule
* Immunization, Secondary
* Immunologic Memory
* Infant
* Injections, Intradermal
* Male
* Time Factors
* Turkey
* Vaccines, Synthetic / administration & dosage

Chemical Compound Name:
(GenHevac B Pasteur); (Hepatitis B Antibodies); (Hepatitis B Vaccines); (Vaccines, Synthetic)
Bookmark URL:

Clinical trial of the intradermal administration of hepatitis B vaccine produced at the Department of Medical Research, Myanmar.
Kyi KP - Vaccine - 22-FEB-2002; 20(11-12): 1649-52
From NIH/NLM MEDLINE

NLM Citation ID:
11858874 (PubMed)
21848603 (MEDLINE)

Full Source Title:
Vaccine

Publication Type:
Clinical Trial; Journal Article

Language:
English

Author Affiliation:
Department of Medical Research (Lower Myanmar), Vaccine Production and Distribution Division, 5 Ziwaka Road, Dagon PO, Yangon 11191, Myanmar.

Authors:
Kyi KP; Oo KM; Htun MM; Tun WM; Aye KK; Oo SS; Lwin KO; Nyunt S

Abstract:
A total of 280 apparently healthy volunteers were screened for hepatitis B (HB) markers out of which 49 subjects (17.5%) were positive for HB surface antigen (HBsAg) and 82 (29.3%) were positive for antibody to HBsAg (anti-HBs). Three doses of DMR-HB vaccine, 0.15 ml per dose were administered to 95 subjects, who were serologically negative for both HB markers. The vaccination was given by the intradermal route on the flexor surface of the left forearm, at 1 month intervals according to the 0, 1 and 2 months schedule. The subjects were carefully monitored to record any adverse reaction of the vaccine. Blood specimen was collected from each subject, 1 month after the second and third vaccinations, to determine the anti-HBs antibody response to the vaccine. The study results showed that local pain was the only side effect noted and protective antibodies (anti-HBs) were detected in 69 (72.6%) of the vaccinees after the second dose of the vaccine and 89 (93.6%) after the third dose of the vaccine. Thus the intradermal route, which would require approximately one-seventh of the standard dose, would be suitable for use in certain groups such as high risk adults, when the cost of the vaccine is the inhibiting factor for routine or mass vaccination.

Major Subjects:

* Hepatitis B Vaccines / * administration & dosage / adverse effects / economics / isolation & purification

Additional Subjects:

* Adult
* Costs and Cost Analysis
* Hepatitis B Antibodies / blood
* Hepatitis B Surface Antigens / blood
* Human
* Immunization Schedule
* Injections, Intradermal
* Male
* Myanmar
* Pain / etiology

Chemical Compound Name:
(Hepatitis B Antibodies); (Hepatitis B Surface Antigens); (Hepatitis B Vaccines)
Bookmark URL:

Comparison of intradermal and intramuscular administration of hepatitis B vaccine in neonates.
Lankarani KB - Indian J Gastroenterol - 01-MAY-2001; 20(3): 94-6
From NIH/NLM MEDLINE

NLM Citation ID:
11400817 (PubMed)
21293647 (MEDLINE)

Comment:
Erratum In:

* Indian J Gastroenterol 2001 Sep-Oct;20(5):212

Full Source Title:
Indian Journal of Gastroenterology

Publication Type:
Clinical Trial; Journal Article; Randomized Controlled Trial

Language:
English

Author Affiliation:
Department of Internal Medicine, Shiraz University of Medical Sciences, Islamic Republic of Iran. [e-mail]

Authors:
Lankarani KB; Taghavi AR; Agah S; Karimi A

Abstract:
BACKGROUND: Hepatitis B virus (HBV) infection and its complications are among the most common diseases in Iran. National mass vaccination of neonates against hepatitis B was started in 1991, but was considered a costly venture. AIM: To compare the efficacy of low-dose intradermal HBV recombinant vaccine with standard intramuscular dose in neonates. METHOD: 165 apparently healthy neonates born in Shiraz were randomized to receive either 10 microg [corrected] of recombinant vaccine intramuscularly (IM; n=82) or 2 microg [corrected] vaccine intradermally (ID; n=83) at months 0, 1, 6. Anti-HBs titers were measured at 6 and 18 months after the first dose. RESULTS: 53 and 51 neonates in the IM and ID groups, respectively, completed the study. Protective anti-HBs titers (>10 IU/L) at 18 months after the first dose were achieved in 98.1% and 96.2% of neonates in IM and ID groups, respectively (p=ns). The only side effect in the ID group was local hyperpigmentation, which was seen in 55%; no significant side effect was reported in the IM group. CONCLUSION: Intradermal vaccination with 20% of standard dose is as effective as IM vaccination when evaluated at 18 months after the first dose.

Major Subjects:

* Hepatitis B Vaccines / * administration & dosage

Additional Subjects:

* Chi-Square Distribution
* Comparative Study
* Female
* Human
* Infant, Newborn
* Injections, Intradermal
* Injections, Intramuscular
* Iran
* Male
* Support, Non-U.S. Gov't

Chemical Compound Name:
(Hepatitis B Vaccines)

[Again, Very Basic Immunology or as dr. Laura Says: "Basic Science".]